Home » Stocks » BEAM

Beam Therapeutics Inc. (BEAM)

Stock Price: $35.20 USD -1.11 (-3.06%)
Updated Oct 30, 2020 11:39 AM EDT - Market open

Stock Price Chart

Key Info

Market Cap 2.00B
Revenue (ttm) 24,000
Net Income (ttm) -119.33M
Shares Out 56.76M
EPS (ttm) -5.08
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 30, 2020
Last Price $35.20
Previous Close $36.31
Change ($) -1.11
Change (%) -3.06%
Day's Open 36.19
Day's Range 34.64 - 36.59
Day's Volume 212,562
52-Week Range 13.00 - 38.89

More Stats

Market Cap 2.00B
Enterprise Value 1.79B
Earnings Date (est) Nov 12, 2020
Ex-Dividend Date n/a
Shares Outstanding 56.76M
Float 30.32M
EPS (basic) n/a
EPS (diluted) -5.08
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 3.64M
Short Ratio 3.46
Short % of Float 11.99%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 83,254.01
PB Ratio 8.48
Revenue 24,000
Operating Income n/a
Net Income -119.33M
Free Cash Flow n/a
Net Cash 205.09M
Net Cash / Share 3.61
Gross Margin 75.00%
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -25.76%
ROE -59.57%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (5)

Buy 5
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$33.75*
(-4.12% downside)
Low
31.0
Current: $35.20
High
40.0
Target: 33.75
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year201920182017
Revenue0.02--
Gross Profit0.02--
Operating Income-75.15-45.74-7.88
Net Income-78.33-115-8.00
Shares Outstanding6.482.890.26
Earnings Per Share-14.05-40.54-37.47
Operating Cash Flow-72.00-20.30-2.71
Capital Expenditures-12.52-13.12-0.35
Free Cash Flow-84.52-33.42-3.05
Cash & Equivalents1051481.93
Total Debt31.2413.75-
Net Cash / Debt73.941341.93
Assets1561672.40
Liabilities55.1532.986.59
Book Value-201-117-9.44
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Beam Therapeutics Inc.
Country United States
Employees 151
CEO John Evans

Stock Information

Ticker Symbol BEAM
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: BEAM
IPO Date February 6, 2020

Description

Beam Therapeutics, a biotechnology company, engages in developing precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing therapies for the development of sickle cell disease and beta-thalassemia; CAR-T cell therapies for pediatric T-cell acute lymphoblastic leukemia and pediatric acute myeloid leukemia; therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1A; and therapies for ocular and central nervous system disorders. It has a research and clinical collaboration agreement with Magenta Therapeutics, Inc. Beam Therapeutics Inc. was founded in 2017 and is based in Cambridge, Massachusetts.